Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;24(3):177-83.
doi: 10.1097/FPC.0000000000000024.

PharmGKB summary: very important pharmacogene information for UGT1A1

Julia M Barbarino  1 , Cyrine E Haidar, Teri E Klein, Russ B Altman
Affiliations
Review

PharmGKB summary: very important pharmacogene information for UGT1A1

Julia M Barbarino et al. Pharmacogenet Genomics. 2014 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
A graphic representation of the human UGT1A locus (not drawn to scale). (a) The locus spans ~200 kbp and contains multiple alternative first exons, which together constitute exon 1. Each unique first exon has its own promoter site. The individual exons for each isoform are combined with the common exons 2–4 and 5a by splicing out any intervening sequence. Exons 2–4 and 5a are therefore present in every UGT1A isoform. However, alternatively spliced UGT1A isoforms do exist, and are known as isoforms 2 or UGT1As_i2; these are created when exon 5b is used instead of, or in addition to, exon 5a. An example of the formation of UGT1A4 mRNA is also shown. In (a) the promoter for UGT1A4 can be seen upstream of the gene, (b) shows the pre-mRNA formed after transcription, and (c) shows the final UGT1A4 mRNA transcript after splicing. Although splicing occurring for common exons 2–5a has not been shown in this figure, it is important to note the absence of exon 5b in (c); this alternative exon has been spliced out to create the classical form of UGT1A4. The figure also shows the location of two important UGT1A1 pharmacogenetic variants, *28 and *6, both of which are discussed in detail within this paper.
See this image and copyright information in PMC

References

    1. Strassburg CP. Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics. 2008;9:703–715. - PubMed
    1. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003;13:517–523. - PubMed
    1. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005;15:677–685. - PubMed
    1. Bushey RT, Dluzen DF, Lazarus P. Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism. Drug Metab Dispos. 2013;41:170–179. - PMC - PubMed
    1. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology. 2001;142:778–787. - PubMed

Publication types

LinkOut - more resources